Request for Proposal: Immune Thrombocytopenic Purpura (ITP)
Novartis Oncology Office of Grants & Education Professional Medical Education
The Novartis Oncology Office of Grants & Education (OGE) supports independent high-quality medical educational programs which provide fair-balanced, evidence-based, current scientific information to healthcare professionals in order to positively improve patient care. Activities should have an educational focus, be independent of commercial bias and be non-promotional in nature. OGE will perform these duties in compliance with laws, regulations and guidelines as established by the ACCME, PhRMA Code, OIG, other regulatory agencies and in compliance with Novartis guidelines and policies.
Immune Thrombocytopenic Purpura (ITP)
RFP Issued: August 12, 2021 Applications Due to Novartis: September 12, 2021 by 5 PM EST Notification of Grant Decisions: October 2021 Educational Programming Starts: Q4 2021 – Q1 2022
Primary ITP is a rare autoimmune disorder characterized by thrombocytopenia (defined as having platelet count < 100,000/μL) in the absence of any known cause. Available epidemiological data for this are very limited, but global incidence of ITP is thought to be about 1.6 to 3.3 per 100,000 persons per year. Patients with ITP often present with bleeding of varying severity, but may be asymptomatic at time of diagnosis. ITP places a substantial burden on health-related quality of life (HRQoL) that may include a fear of bleeding and experience of unexplained lack of energy. Patients with ITP incur greater medical resource use, miss more work or school days and have significantly worse productivity compared to those without ITP.
American Society of Hematology (ASH) practice guidelines for ITP in 2019 address management of both adult and pediatric ITP. In adults with ITP, initial therapy generally includes oral corticosteroids and/or intravenous immunoglobulins (IVIg and anti-D) resulting in normal or “safe” platelet counts in about 65%-70% of ITP patients. In children with ITP, observation alone is recommended over hospital admission or treatment with corticosteroids, IVIg, or anti-D. However, only 13%-17% of ITP patients achieve sustained platelet response after 12 months when corticosteroid is discontinued.
OGE has identified the need for innovative continuing medical education programs that strive to optimize patient outcomes through education on:
The current and emerging treatment landscape in first line and second line settings of immune thrombocytopenia
The long-term management strategies with persistent/chronic ITP to endure optimal patient outcomes and adherence
The various pathways in treating ITP
OGE is seeking to support:
Virtual/Live community-based educational series of case-based programs held in community hospitals, heme/onc academic centers, along with an enduring component.
Virtual/Live programs with enduring component (stand-alone or in conjunction with ITP related medical societies, congresses)
Note: Program placement is independent of Novartis. Program placement should reflect nationwide distribution in locations in which patients with ITP obtain treatment.
National, Regional, and/or Local
Healthcare providers who are involved in the care of patients with ITP, including but not limited to: Hematologists/Oncologists, Pediatric Hematologists, Nurses, Nurse Practioners, Physician Assistants, Pharmacists, Payers
Educational providers should include target number of participants. Further, please include details on proposed audience recruitment. Please note: Novartis will not participate in the distribution of invitations to the CME/CE event.
Multiple single-support or multi-support initiatives may be funded; Up to $300,000 in total support is available.
If working with an Accredited Provider and/or Educational Partner, they should be listed in the Novartis grant application. Grant requests must be submitted by the Office of CME (if from an Academic Institution/Hospital) via the Online Portalby 5 PM EST on September 12, 2021 to be considered.
The grant application should include “RFP Response” within the Program Title [example: “RFP Response: Program Title”].
Proposals that include collaborations with third parties, including (but not limited to), medical societies, health education companies/centers, not-for-profit organizations, and academic institutions, are encouraged, as appropriate.